163 related articles for article (PubMed ID: 18648129)
1. Translational research in pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Saif MW
JOP; 2008 Jul; 9(4):398-402. PubMed ID: 18648129
[TBL] [Abstract][Full Text] [Related]
2. New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Saif MW
JOP; 2008 Jul; 9(4):391-7. PubMed ID: 18648128
[TBL] [Abstract][Full Text] [Related]
3. Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Makrilia N; Syrigos KN; Saif MW
JOP; 2011 Jul; 12(4):351-4. PubMed ID: 21737894
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
Saif MW
JOP; 2007 Jul; 8(4):365-73. PubMed ID: 17625289
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
Saif MW
JOP; 2006 Jul; 7(4):337-48. PubMed ID: 16832131
[TBL] [Abstract][Full Text] [Related]
7. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
[TBL] [Abstract][Full Text] [Related]
8. Screening for early pancreatic ductal adenocarcinoma: an urgent call!
Lee MX; Saif MW
JOP; 2009 Mar; 10(2):104-8. PubMed ID: 19287101
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
Chen J; Li D; Killary AM; Sen S; Amos CI; Evans DB; Abbruzzese JL; Frazier ML
Ann Surg Oncol; 2009 Feb; 16(2):431-9. PubMed ID: 19020940
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival.
Heger U; Sun H; Hinz U; Klaiber U; Tanaka M; Liu B; Sachsenmaier M; Springfeld C; Michalski CW; Büchler MW; Hackert T
HPB (Oxford); 2020 Feb; 22(2):224-232. PubMed ID: 31375338
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Merl MY; Abdelghany O; Li J; Saif MW
JOP; 2010 Jul; 11(4):317-20. PubMed ID: 20601801
[TBL] [Abstract][Full Text] [Related]
12. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer.
Kamisawa T; Wood LD; Itoi T; Takaori K
Lancet; 2016 Jul; 388(10039):73-85. PubMed ID: 26830752
[TBL] [Abstract][Full Text] [Related]
14.
Sinn M; Sinn BV; Treue D; Keilholz U; Damm F; Schmuck R; Lohneis P; Klauschen F; Striefler JK; Bahra M; Bläker H; Bischoff S; Pelzer U; Oettle H; Riess H; Budczies J; Denkert C
Clin Cancer Res; 2020 Jul; 26(14):3732-3739. PubMed ID: 32234756
[TBL] [Abstract][Full Text] [Related]
15. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Chung KH; Ryu JK; Lee BS; Jang DK; Lee SH; Kim YT
J Gastroenterol Hepatol; 2016 Feb; 31(2):506-12. PubMed ID: 26250642
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma].
Kawaida H; Fujii H
Nihon Rinsho; 2015 Mar; 73 Suppl 3():181-5. PubMed ID: 25857011
[No Abstract] [Full Text] [Related]
17. Updates on first-line treatment of metastatic pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2011 Jul; 12(4):339-42. PubMed ID: 21737891
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Seufferlein T; Bachet JB; Van Cutsem E; Rougier P;
Ann Oncol; 2012 Oct; 23 Suppl 7():vii33-40. PubMed ID: 22997452
[No Abstract] [Full Text] [Related]
19. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic tools in pancreatic cancer.
Hoimes CJ; Strimpakos AS; Saif MW
JOP; 2009 Mar; 10(2):118-22. PubMed ID: 19287103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
